Literature DB >> 2549348

Prevalence of antibody to human herpesvirus 6 in women and children.

K Balachandra1, P I Ayuthaya, W Auwanit, C Jayavasu, T Okuno, K Yamanishi, M Takahashi.   

Abstract

The antibody prevalence to human herpesvirus 6 (HHV-6) was compared between pregnant women and control women of similar ages in Thailand. No significant difference was detected in the antibody positive rate and antibody titers between both groups. The antibody titers in sera collected from pregnant women at 1st and 3rd trimester remained unchanged. Next, the antibody prevalence in infants were examined and the positive rate decreased until 3 months and started to increase from 6 months after birth. The present results suggest that the reactivation of HHV-6 might not occur during pregnancy and this virus infects infants postnatally.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2549348     DOI: 10.1111/j.1348-0421.1989.tb02001.x

Source DB:  PubMed          Journal:  Microbiol Immunol        ISSN: 0385-5600            Impact factor:   1.955


  5 in total

Review 1.  Human herpesvirus 6.

Authors:  D K Braun; G Dominguez; P E Pellett
Journal:  Clin Microbiol Rev       Date:  1997-07       Impact factor: 26.132

2.  Real-time quantitative PCR for human herpesvirus 6 DNA.

Authors:  G Locatelli; F Santoro; F Veglia; A Gobbi; P Lusso; M S Malnati
Journal:  J Clin Microbiol       Date:  2000-11       Impact factor: 5.948

3.  Seroprevalence of antibodies against human herpesvirus 6 in the Quebec City area.

Authors:  L Deschênes; J R Joly; M Couillard; G Richer
Journal:  Can J Infect Dis       Date:  1992-07

4.  Human herpesvirus 7: antigenic properties and prevalence in children and adults.

Authors:  L S Wyatt; W J Rodriguez; N Balachandran; N Frenkel
Journal:  J Virol       Date:  1991-11       Impact factor: 5.103

5.  Primary infections of Epstein-Barr virus, cytomegalovirus, and human herpesvirus-6.

Authors:  L M Huang; C Y Lee; M H Chang; J D Wang; C Y Hsu
Journal:  Arch Dis Child       Date:  1993-03       Impact factor: 3.791

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.